Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC
Interim ASCO Data Show Improvement in PD-L1 Expressors, All-Comers
Executive Summary
An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.
You may also be interested in...
Keytruda Adjuvant Kidney Cancer Data Cement The Future Of IO
The data illustrate the growing importance of adjuvant settings of solid tumors for PD-1/PD-L1 inhibitors, which could make up more than one-quarter of their sales in 2025.
Finance Watch: IPO Momentum Slows But Biopharma Stocks Get An ASCO Bump
Public Company Edition: There was just one initial public offering during the past two weeks, but another biotech-focused SPAC went public and Gingko Bioworks announced a high-value SPAC merger. Also, Insmed and Dynavax offerings led recent public company financings.
Merck & Co.’s Keytruda Gets Fighting Chance In TNBC
The company previously was unsuccessful securing accelerated approval based on complete response data, but event-free survival results may be more persuasive.